Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 30.25M P/E - EPS this Y 64.00% Ern Qtrly Grth -
Income -34.97M Forward P/E -0.13 EPS next Y -27.20% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 1.76 EPS next 5Y - 52W High Chg -48.00%
Recommedations 1.60 Quick Ratio 6.13 Shares Outstanding 12.04M 52W Low Chg 225.00%
Insider Own 0.76% ROA -25.68% Shares Float 9.47M Beta 2.57
Inst Own 102.35% ROE -51.78% Shares Shorted/Prior 1.26M/1.22M Price 6.86
Gross Margin - Profit Margin - Avg. Volume 25,833 Target Price 63.00
Oper. Margin - Earnings Date Nov 5 Volume 7,185 Change -5.25%
About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings News
11/21/24 Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
11/12/24 Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11/09/24 We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
11/07/24 Corbus Pharmaceuticals: Q3 Earnings Snapshot
11/07/24 Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
11/04/24 Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
11/04/24 Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
10/29/24 Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
10/16/24 Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
10/03/24 Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts?
09/26/24 Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
09/24/24 Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals
09/20/24 Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
09/05/24 Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
09/04/24 Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now
08/27/24 Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
08/26/24 Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
08/20/24 Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
08/11/24 With 59% ownership, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) boasts of strong institutional backing
08/09/24 Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
CRBP Chatroom

User Image Thorpe Posted - 15 hours ago

$CRBP Picking up, but very low volume. We need an update from Jefferies, but probably won’t see it knowing this companies PR.

User Image Thorpe Posted - 1 day ago

$CRBP This Leadership team doesn’t update much, but they are going after investors at least. They are currently in a conference at Jefferies in London through today. They and have another scheduled Dec 3rd-5th at Evercore HealthCONx. Give us some news that will sky rocket this back to $60 in 2025. https://finance.yahoo.com/news/corbus-pharmaceuticals-present-7th-annual-130000948.html

User Image Willie3000 Posted - 2 days ago

$CRBP LOL. Ridiculous. Tempted to add, but will hold off for now. Still long.

User Image Thorpe Posted - 2 days ago

$CRBP Entire market down awaiting $NVDA earnings. Better be good.

User Image Thorpe Posted - 2 days ago

$CRBP Cheap ass shares. Entire market red.

User Image Luella_Salinas Posted - 2 days ago

$CRBP $ETON $FULC LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image justiceforb_85 Posted - 3 days ago

$CRBP do we know which tumors CRB-601 is targeting?

User Image Thorpe Posted - 4 days ago

$CRBP Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference to be held November 19-21, 2024 in London, UK.

User Image WallStreetBuyDip Posted - 6 days ago

I make this so that it’s easy for anyone to see how I make my trades using H%. Many traders buy the random level and lose while I get a reversal trade 95%+ of the time. Learn what low H% is. Will buy $CRBP for a reversal trade when H% is low. What’s your strategy in the market when making a trade? Algos are very complex. This shows why I only buy when H% is low.

User Image Thorpe Posted - 1 week ago

$CRBP Adding……again.

User Image Willie3000 Posted - 1 week ago

$CRBP such bullsh*t

User Image Fugazi_ Posted - 1 week ago

$CRBP This went up because of CRB-701 trial data back in January (cancer drug) was positive, then collapsed 8 months later due to Novo Nordisk's data on a completely different drug, (weight loss). Even though CRBP does glp-1 at pre-clinical testing, I find this history very odd🤔

User Image Thorpe Posted - 1 week ago

$CRBP this is market fluctuations. All indices down and cooling off. Buy more

User Image CookamungaCrackerKillaz Posted - 1 week ago

$CRBP so it was shit earnings?

User Image rangerhawkeye Posted - 1 week ago

$CRBP trying some here

User Image Thorpe Posted - 1 week ago

$CRBP https://finance.yahoo.com/news/corbus-pharmaceuticals-present-jefferies-london-130000935.html

User Image kuwshlavi Posted - 1 week ago

$CRBP smfh now it's just a sounding board for other stocks.

User Image Biotech2424 Posted - 1 week ago

$CHRS Baby Keytruda Buy 100,000 shares and move stock to a cash account. So shorts can’t borrow. I am moving all my stock next week. $350 million revenues in 2025 and trading at normal 3.5x revenues equals upside if trading at 1x sales equals $10.62 stock price. Free $$ and very minimal risk getting back to $1.33 which is same valuation as $PBYI on a market cap basis. $150 million. They have $200 mil revs. Shorts lose $3 million every 10 cents it goes up. At this tiny valuation shorts are paying more in carrying costs - should be covering soon. (Margin, Borrow, missed opportunities) $SMMT $CRBP $ELEV

User Image cashflowismyhobby Posted - 2 weeks ago

$CRBP a patience play.

User Image Cricket23 Posted - 2 weeks ago

$CRBP CRBP will return to glory after seeing the earning report today and corporate update. The company is providing only positive news and updates. Investors will continue to take notice of the positive news and stock price will be at $25 shortly.

User Image Fugazi_ Posted - 2 weeks ago

$CRBP they reported earnings but not a single earnings post here thats new

User Image kuwshlavi Posted - 2 weeks ago

$CRBP guess that's it got my last bit of calls..smh

User Image Thorpe Posted - 2 weeks ago

$CRBP saw this drop coming. Financials need work and we need a big catalyst. Will gobble and load at the bottom. 2025 will be big.

User Image Thorpe Posted - 2 weeks ago

$CRBP Nice spike at $20.77. Hope bulls nibbled some profits.

User Image roscoe44 Posted - 2 weeks ago

$CRBP ebs capr soun these tickers on my portfolio are on fire.

User Image OMillionaires Posted - 2 weeks ago

$23 the big spot for $CRBP

User Image Kelcebros Posted - 2 weeks ago

$CRBP $20! lets get this to $40

User Image Thorpe Posted - 2 weeks ago

$CRBP Nice early morning boost !

User Image Thorpe Posted - 2 weeks ago

$CRBP I sold large portion of my shares pre-market at $19.25. I am bullish long term. Will get back in on dips.

User Image Thorpe Posted - 2 weeks ago

$CRBP should be interesting day today. Hard to decipher how the market will interpret the loss vs progress on development pipeline. Corbus Pharmaceuticals, an oncology and obesity-focused company, reported a net loss of $13.8 million for Q3 2024, attributing increased costs to clinical trials and compensation expenses. The company is advancing its diverse drug pipeline, including CRB-701 for cancer and CRB-913 for obesity, with significant data expected in early 2025. With $159.4 million in cash reserves, Corbus is poised to fund operations through Q3 2027 and continues to innovate in targeting well-understood biological pathways.

Analyst Ratings
RBC Capital Outperform Aug 7, 24
Oppenheimer Outperform Aug 7, 24
HC Wainwright & Co. Buy Aug 6, 24
Oppenheimer Outperform Jul 10, 24
B. Riley Securities Buy Jun 26, 24
RBC Capital Outperform Jun 11, 24
Oppenheimer Outperform Jun 3, 24
RBC Capital Outperform May 13, 24
Oppenheimer Outperform May 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
HOLMER ALAN F Director Director Jan 26 Option 4.97 629 3,126 1,379 01/30/24
Cohen Yuval Chief Executive Offi.. Chief Executive Officer Jan 26 Option 4.97 7,179 35,680 7,179 01/30/24
Millian Craig Stuart Chief Operating Offi.. Chief Operating Officer Aug 10 Buy 0.2545 5,000 1,272 27,000 08/12/22
Cohen Yuval Chief Executive Offi.. Chief Executive Officer Aug 10 Buy 0.264 3,800 1,003 98,230 08/11/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Aug 10 Buy 0.2599 20,000 5,198 199,272 08/10/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer May 16 Buy 0.30 12,000 3,600 179,272 05/16/22
Cohen Yuval Chief Executive Offi.. Chief Executive Officer May 16 Buy 0.25 10,500 2,625 94,430 05/16/22
Millian Craig Stuart Chief Operating Offi.. Chief Operating Officer Mar 10 Buy 0.37 10,000 3,700 22,000 03/11/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Mar 10 Buy 0.37 15,000 5,550 167,272 03/10/22
Cohen Yuval Chief Executive Offi.. Chief Executive Officer Mar 09 Buy 0.37 8,600 3,182 83,930 03/09/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Dec 18 Option 0.17 36,923 6,277 386,533 12/18/20
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 1.32 36,923 48,738 349,610 12/18/20